Beyond CAR-T cells: Natural killer cells immunotherapy

Sánchez, María Dolores Corral; Casanova, Lucía Fernández; Pérez‐Martínez, Antonio

doi:10.1016/j.medcle.2019.08.004

Cited by 2 publications

(1 citation statement)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Allogenic T cells express the human leucocyte antigen (HLA), which can give a mismatch between donor and recipient, leading to severe, even lethal graft-versus-host disease (GvHD) [74]. This leads to a new source of cells, since the less alloreactive T cell subset such as CD45RAlymphocytes [75] and Natural Killer (NK) cells are good candidates because they suppress GvHD by inhibiting activated, alloreactive T cells without causing GvHD themselves [76,77]. NK lymphocytes constitute an attractive source for CAR-based treatments, owing to their innate ability to kill malignant or infected cells without prior activation or HLA restriction [78].…”

Section: Advantages and Disadvantages Of Car-nk And Car-t Therapiesmentioning

confidence: 99%

The Race of CAR Therapies: CAR-NK Cells for Fighting B-Cell Hematological Cancers

Herrera

Santos

Vesga

et al. 2021

Cancers

Self Cite

View full text Add to dashboard Cite

Acute lymphoblastic leukemia (ALL) and Chronic lymphocytic leukemia (CLL) are the most common leukemias in children and elderly people, respectively. Standard therapies, such as chemotherapy, are only effective in 40% of ALL adult patients with a five-year survival rate and therefore new alternatives need to be used, such as immunotherapy targeting specific receptors of malignant cells. Among all the options, CAR (Chimeric antigen receptor)-based therapy has arisen as a new opportunity for refractory or relapsed hematological cancer patients. CARs were designed to be used along with T lymphocytes, creating CAR-T cells, but they are presenting such encouraging results that they are already in use as drugs. Nonetheless, their side-effects and the fact that it is not possible to infuse an allogenic CAR-T product without causing graft-versus-host-disease, have meant using a different cell source to solve these problems, such as Natural Killer (NK) cells. Although CAR-based treatment is a high-speed race led by CAR-T cells, CAR-NK cells are slowly (but surely) consolidating their position; their demonstrated efficacy and the lack of undesirable side-effects is opening a new door for CAR-based treatments. CAR-NKs are now in the field to stay.

show abstract

Section: Advantages and Disadvantages Of Car-nk And Car-t Therapiesmentioning

confidence: 99%

The Race of CAR Therapies: CAR-NK Cells for Fighting B-Cell Hematological Cancers

Herrera

Santos

Vesga

et al. 2021

Cancers

Self Cite

View full text Add to dashboard Cite

show abstract

CAR T Cell Therapy for Chronic Lymphocytic Leukemia: Successes and Shortcomings

Todorović

Markovic

et al. 2022

Current Oncology

View full text Add to dashboard Cite

Chimeric antigen receptor T (CAR T) cell therapy achieved remarkable success in B-cell leukemia and lymphoma which led to its incorporation in treatment protocols for these diseases. CAR T cell therapy for chronic lymphocytic leukemia (CLL) patients showed less success compared to other malignant tumors. In this review, we discuss the published results regarding CAR T cell therapy of CLL, possible mechanisms of failures and expected developments.

show abstract

Beyond CAR-T cells: Natural killer cells immunotherapy

Cited by 2 publications

References 57 publications

The Race of CAR Therapies: CAR-NK Cells for Fighting B-Cell Hematological Cancers

The Race of CAR Therapies: CAR-NK Cells for Fighting B-Cell Hematological Cancers

CAR T Cell Therapy for Chronic Lymphocytic Leukemia: Successes and Shortcomings

Contact Info

Product

Resources

About